1,606 research outputs found
Radiation-driven winds of hot luminous stars XVII. Parameters of selected central stars of PN from consistent optical and UV spectral analysis and the universality of the mass-luminosity relation
Context: The commonly accepted mass-luminosity relation of central stars of
planetary nebulae (CSPNs) might not be universally valid. While earlier optical
analyses could not derive masses and luminosities independently (instead taking
them from theoretical evolutionary models) hydrodynamically consistent
modelling of the stellar winds allows using fits to the UV spectra to
consistently determine also stellar radii, masses, and luminosities without
assuming a mass-luminosity relation. Recent application to a sample of CSPNs
raised questions regarding the validity of the theoretical mass-luminosity
relation of CSPNs.
Aims: The results of the earlier UV analysis are reassessed by means of a
simultaneous comparison of observed optical and UV spectra with corresponding
synthetic spectra.
Methods: Using published stellar parameters (a) from a consistent UV analysis
and (b) from fits to optical H and He lines, we calculate simultaneous optical
and UV spectra with our model atmosphere code, which has been improved by
implementing Stark broadening for H and He lines.
Results: Spectra computed with the parameter sets from the UV analysis yield
good agreement to the observations, but spectra computed with the stellar
parameters from the published optical analysis and using corresponding
consistent wind parameters show large discrepancies to both the observed
optical and UV spectra. The published optical analyses give good fits to the
observed spectrum only because the wind parameters assumed in these analyses
are inconsistent with their stellar parameters. By enforcing consistency
between stellar and wind parameters, stellar parameters are obtained which
disagree with the core-mass-luminosity relation for the objects analyzed. This
disagreement is also evident from a completely different approach: an
investigation of the dynamical wind parameters.Comment: 22 pages, 18 fugre
Wig-1, a novel regulator of N-Myc mRNA and N-Myc-driven tumor growth
Wig-1 is a transcriptional target of the p53 tumor suppressor and encodes an mRNA stability-regulating protein. We show here that Wig-1 knockdown causes a dramatic inhibition of N-Myc expression and triggers differentiation in neuroblastoma cells carrying amplified N-Myc. Transient Wig-1 knockdown significantly delays development of N-Myc-driven tumors in mice. We also show that N-Myc expression is induced upon moderate p53-activating stress, suggesting a role of the p53-Wig-1-N-Myc axis in promoting cell cycle re-entry upon p53-induced cell cycle arrest and DNA repair. Moreover, our findings raise possibilities for the improved treatment of poor prognosis neuroblastomas that carry amplified N-Myc
Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE
Objective: Our aim was to provide practical recommendations on the management of patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel plus androgen-deprivation therapy (ADT) or abiraterone plus ADT.
Methods: Systematic literature review (SLR), nominal group meeting, and Delphi process. A panel of 12 experts was established who defined the scope, users, and sections of the document. We performed an SLR in order to assess the efficacy and safety of available drugs in patients with mCRPC. Abstracts from the American Society of Oncology and European Society for Medical Oncology meetings were also examined. The results were discussed during an expert meeting in which 14 recommendations were generated. The level of agreement with the recommendations was also tested by 13 additional experts following the Delphi process. Recommendations were voted by means of scores ranging from 0 (total disagreement) to 10 (total agreement). We defined agreement when at least 70% of the experts voted Âż7. Next, we assigned a level of evidence and grade to the recommendation using the Oxford Centre for Evidence-based Medicine Levels of Evidence, following which the final document was drafted. Results: The literature search did not find any articles meeting the inclusion criteria. Finally, 13 out of 14 recommendations were accepted after two Delphi rounds (two were modified after the first round). They pertain to general and individual case-based treatment recommendations.
Conclusions: In mCRPC patients who have progressed after docetaxel or abiraterone plus ADT in the metastatic hormone-sensitive prostate cancer setting, these recommendations may support treatment decision-making, due to the lack of evidence or other globally accepted sequencing algorithms
Pck1 Gene Silencing in the Liver Improves Glycemia Control, Insulin Sensitivity, and Dyslipidemia in db/db Mice
OBJECTIVEâCytosolic phosphoenolpyruvate carboxykinase (PEPCK-C; encoded by Pck1) catalyzes the first committed step in gluconeogenesis. Extensive evidence demonstrates a direct correlation between PEPCK-C activity and glycemia control. Therefore, we aimed to evaluate the metabolic impact and their underlying mechanisms of knocking down hepatic PEPCK-C in a type 2 diabetic model
Genomic Analysis of wig-1 Pathways
Background: Wig-1 is a transcription factor regulated by p53 that can interact with hnRNP A2/B1, RNA Helicase A, and dsRNAs, which plays an important role in RNA and protein stabilization. in vitro studies have shown that wig-1 binds p53 mRNA and stabilizes it by protecting it from deadenylation. Furthermore, p53 has been implicated as a causal factor in neurodegenerative diseases based in part on its selective regulatory function on gene expression, including genes which, in turn, also possess regulatory functions on gene expression. In this study we focused on the wig-1 transcription factor as a downstream p53 regulated gene and characterized the effects of wig-1 down regulation on gene expression in mouse liver and brain. Methods and Results: Antisense oligonucleotides (ASOs) were identified that specifically target mouse wig-1 mRNA and produce a dose-dependent reduction in wig-1 mRNA levels in cell culture. These wig-1 ASOs produced marked reductions in wig-1 levels in liver following intraperitoneal administration and in brain tissue following ASO administration through a single striatal bolus injection in FVB and BACHD mice. Wig-1 suppression was well tolerated and resulted in the reduction of mutant Htt protein levels in BACHD mouse brain but had no effect on normal Htt protein levels nor p53 mRNA or protein levels. Expression microarray analysis was employed to determine the effects of wig-1 suppression on genome-wide expression in mouse liver and brain. Reduction of wig-1 caused both down regulation and up regulation of several genes
Phase I and pharmacokinetics study of crotoxin (cytotoxic PLA(2), NSC-624244) in patients with advanced cancer
Fil: Cura, Jorge E. Hospital San MartĂn. Departamento de Medicina OncolĂłgica, ParanĂĄ; Entre RĂos.Fil: Blanzaco, Daniel P. Hospital San MartĂn. Departamento de Medicina OncolĂłgica, ParanĂĄ; Entre RĂos.Fil: Brisson, Cecilia. Hospital San MartĂn. Departamento de Medicina OncolĂłgica, ParanĂĄ; Entre RĂos.Fil: Cura, Marco A. Hospital San MartĂn. Departamento de Medicina OncolĂłgica, ParanĂĄ; Entre RĂos.Fil: Cabrol, Rosa. Hospital San MartĂn. Departamento de Medicina OncolĂłgica, ParanĂĄ; Entre RĂos.Fil: Larrateguy, Luis. Hospital San MartĂn. Departamento de Medicina OncolĂłgica, ParanĂĄ; Entre RĂos.Fil: Mendez, Carlos. Hospital San MartĂn. Departamento de Medicina OncolĂłgica, ParanĂĄ; Entre RĂos.Fil: Sechi, Jose Carlos. Hospital San MartĂn. Departamento de Medicina OncolĂłgica, ParanĂĄ; Entre RĂos.Fil: Silveira, Jorge Solana. Hospital San MartĂn. Departamento de Medicina OncolĂłgica, ParanĂĄ; Entre RĂos.Fil: Theiller, Elvira. Hospital San MartĂn. Departamento de Medicina OncolĂłgica, ParanĂĄ; Entre RĂos.Fil: de Roodt, Adolfo R. ANLIS Dr.C.G.MalbrĂĄn. Instituto Nacional de ProducciĂłn de BiolĂłgicos; Argentina.Fil: Vidal, Juan Carlos. ANLIS Dr.C.G.MalbrĂĄn. Instituto Nacional de ProducciĂłn de BiolĂłgicos; Argentina.A Phase I clinical trial was performed on patients with solid tumors refractory to conventional therapy. Crotoxin was administered i.m. for 30 consecutive days at doses ranging from 0.03 to 0.22 mg/m(2). Patients entered the study after providing a written informed consent. Although 26 patients were entered only 23 were evaluated. Reversible, nonlimiting neuromuscular toxicity evidenced as diplopia because of pareses of the external ocular muscles was present in 13 patients. It started at doses of 0.18 mg/m(2) and lasted from 2 to 6 h. These episodes did not require dose adjustment and disappeared in 1-3 weeks of treatment. Three patients experienced palpebral ptosis, nystagmus (grade 2), and anxiety (grade 2-3) at the dose-limiting toxicity of 0.22 mg/m(2). Also at dose-limiting toxicity, 1 patient showed nystagmus (grade 2) and anxiety (grade 3) without evidence of palpebral ptosis. Transient increases (grades 1-3) in the levels of creatinine kinase, aspartate aminotransferase, and alanine transaminase attributed to crotoxin myotoxicity were observed but returned to normal by the last week of treatment. At 0.21 mg/m(2) there was a case of grade-3 anaphylactic reaction on day 31, which required treatment. Hypersensitivity was regarded as an adverse drug-related reaction, and the patient was removed from the protocol. Two patients at different doses (0.12 mg/m(2) and 0.22 mg/m(2)) had sialorrhea. Four patients had asymptomatic transient increase in blood pressure (up to 20 mm Hg) 12 h after the first injection, which lasted 24 h. No treatment was required and toxicity did not reappear. Six patients experienced slight eosinophilia during the first 2 weeks. The maximum tolerated dose was set at 0.21 mg/m(2). Objective measurable partial responses (>50% reduction of tumor mass) were noted in 2 patients treated at 0.21 mg/m(2) and 1 at 0.12 mg/m(2). One patient (at 0.21 mg/m(2)) presented a complete response on day 110. Crotoxin pharmacokinetics showed rapid absorption from the injection site to blood (t(1/2 A) = 5.2 +/- 0.6 min). Plasma concentration reached a peak (C(max) = 0.79 +/- 0.1 ng/ml) at tau(max) = 19 +/- 3 min. The half-life of the distribution (alpha) phase is 22 +/- 2 min. Starting at 1.5 h after injection, the decrease in plasma concentration becomes slower, reaching 14 +/- 3 pg/ml 24 h after injection. The profile is dominated by the elimination (beta) phase with a half-life of 5.2 +/- 0.6 h. Consequently, 24 h after the injection ( approximately 5 half-life) 97% of the product was eliminated. The area under plasma concentration versus time curve was 0.19 +/- 0.05 microg/min/ml. Assuming availability (F) approximately 1, the clearance is C(L) = 26.3 +/- 7 ml/min, and the apparent volume of distribution is V(d) = 12 +/- 3 liter/kg. The recommended dose for a Phase II study is 0.18 mg/m(2)
Phase I and pharmacokinetics study of crotoxin (cytotoxic PLA(2), NSC-624244) in patients with advanced cancer
Fil: Cura, Jorge E. Hospital San MartĂn. Departamento de Medicina OncolĂłgica, ParanĂĄ; Entre RĂos.Fil: Blanzaco, Daniel P. Hospital San MartĂn. Departamento de Medicina OncolĂłgica, ParanĂĄ; Entre RĂos.Fil: Brisson, Cecilia. Hospital San MartĂn. Departamento de Medicina OncolĂłgica, ParanĂĄ; Entre RĂos.Fil: Cura, Marco A. Hospital San MartĂn. Departamento de Medicina OncolĂłgica, ParanĂĄ; Entre RĂos.Fil: Cabrol, Rosa. Hospital San MartĂn. Departamento de Medicina OncolĂłgica, ParanĂĄ; Entre RĂos.Fil: Larrateguy, Luis. Hospital San MartĂn. Departamento de Medicina OncolĂłgica, ParanĂĄ; Entre RĂos.Fil: Mendez, Carlos. Hospital San MartĂn. Departamento de Medicina OncolĂłgica, ParanĂĄ; Entre RĂos.Fil: Sechi, Jose Carlos. Hospital San MartĂn. Departamento de Medicina OncolĂłgica, ParanĂĄ; Entre RĂos.Fil: Silveira, Jorge Solana. Hospital San MartĂn. Departamento de Medicina OncolĂłgica, ParanĂĄ; Entre RĂos.Fil: Theiller, Elvira. Hospital San MartĂn. Departamento de Medicina OncolĂłgica, ParanĂĄ; Entre RĂos.Fil: de Roodt, Adolfo R. ANLIS Dr.C.G.MalbrĂĄn. Instituto Nacional de ProducciĂłn de BiolĂłgicos; Argentina.Fil: Vidal, Juan Carlos. ANLIS Dr.C.G.MalbrĂĄn. Instituto Nacional de ProducciĂłn de BiolĂłgicos; Argentina.A Phase I clinical trial was performed on patients with solid tumors refractory to conventional therapy. Crotoxin was administered i.m. for 30 consecutive days at doses ranging from 0.03 to 0.22 mg/m(2). Patients entered the study after providing a written informed consent. Although 26 patients were entered only 23 were evaluated. Reversible, nonlimiting neuromuscular toxicity evidenced as diplopia because of pareses of the external ocular muscles was present in 13 patients. It started at doses of 0.18 mg/m(2) and lasted from 2 to 6 h. These episodes did not require dose adjustment and disappeared in 1-3 weeks of treatment. Three patients experienced palpebral ptosis, nystagmus (grade 2), and anxiety (grade 2-3) at the dose-limiting toxicity of 0.22 mg/m(2). Also at dose-limiting toxicity, 1 patient showed nystagmus (grade 2) and anxiety (grade 3) without evidence of palpebral ptosis. Transient increases (grades 1-3) in the levels of creatinine kinase, aspartate aminotransferase, and alanine transaminase attributed to crotoxin myotoxicity were observed but returned to normal by the last week of treatment. At 0.21 mg/m(2) there was a case of grade-3 anaphylactic reaction on day 31, which required treatment. Hypersensitivity was regarded as an adverse drug-related reaction, and the patient was removed from the protocol. Two patients at different doses (0.12 mg/m(2) and 0.22 mg/m(2)) had sialorrhea. Four patients had asymptomatic transient increase in blood pressure (up to 20 mm Hg) 12 h after the first injection, which lasted 24 h. No treatment was required and toxicity did not reappear. Six patients experienced slight eosinophilia during the first 2 weeks. The maximum tolerated dose was set at 0.21 mg/m(2). Objective measurable partial responses (>50% reduction of tumor mass) were noted in 2 patients treated at 0.21 mg/m(2) and 1 at 0.12 mg/m(2). One patient (at 0.21 mg/m(2)) presented a complete response on day 110. Crotoxin pharmacokinetics showed rapid absorption from the injection site to blood (t(1/2 A) = 5.2 +/- 0.6 min). Plasma concentration reached a peak (C(max) = 0.79 +/- 0.1 ng/ml) at tau(max) = 19 +/- 3 min. The half-life of the distribution (alpha) phase is 22 +/- 2 min. Starting at 1.5 h after injection, the decrease in plasma concentration becomes slower, reaching 14 +/- 3 pg/ml 24 h after injection. The profile is dominated by the elimination (beta) phase with a half-life of 5.2 +/- 0.6 h. Consequently, 24 h after the injection ( approximately 5 half-life) 97% of the product was eliminated. The area under plasma concentration versus time curve was 0.19 +/- 0.05 microg/min/ml. Assuming availability (F) approximately 1, the clearance is C(L) = 26.3 +/- 7 ml/min, and the apparent volume of distribution is V(d) = 12 +/- 3 liter/kg. The recommended dose for a Phase II study is 0.18 mg/m(2)
ĐОкаСаŃоНи каŃĐľŃŃва МиСни, ŃвŃСаннОгО ŃĐž СдОŃОвŃоП, Ń ĐżĐ°ŃионŃОв Ń ŃĐ°ŃĐżŃĐžŃŃŃаноннŃĐź пОŃĐľŃнО-кНоŃĐžŃĐ˝ŃĐź ŃакОП ĐżŃи НоŃонии НонваŃинийОП в кОПйинаŃии Ń ĐżĐľĐźĐąŃОНиСŃПайОП иНи ŃвоŃОНиПŃŃОП пО ŃŃĐ°Đ˛Đ˝ĐľĐ˝Đ¸Ń Ń ĐźĐžĐ˝ĐžŃĐľŃапиоК ŃŃниŃинийОП (CLEAR): ŃандОПиСиŃОваннОо кНиниŃĐľŃкОо иŃŃНодОванио III ŃаСŃ
.Đводонио. РоСŃĐťŃŃĐ°ŃŃ ĐşĐťĐ¸Đ˝Đ¸ŃĐľŃкОгО иŃŃĐťĐľĐ´ĐžĐ˛Đ°Đ˝Đ¸Ń III ŃĐ°ĐˇŃ CLEAR пОкаСаНи, ŃŃĐž кОПйинаŃĐ¸Ń ĐťĐľĐ˝Đ˛Đ°Ńинийа и поПйŃОНиСŃПайа ŃвоНиŃĐ¸Đ˛Đ°ĐľŃ Đ˛ŃМиваоПОŃŃŃ ĐąĐľĐˇ ĐżŃОгŃĐľŃŃиŃĐžĐ˛Đ°Đ˝Đ¸Ń Đ¸ ОйŃŃŃ Đ˛ŃМиваоПОŃŃŃ ĐżĐž ŃŃĐ°Đ˛Đ˝ĐľĐ˝Đ¸Ń Ń ĐźĐžĐ˝ĐžŃĐľŃапиоК ŃŃниŃинийОП Ń ĐżĐ°ŃионŃОв Ń ŃĐ°ŃĐżŃĐžŃŃŃаноннŃĐź пОŃĐľŃнО-кНоŃĐžŃĐ˝ŃĐź ŃакОП.ĐŚĐľĐťŃ Đ¸ŃŃĐťĐľĐ´ĐžĐ˛Đ°Đ˝Đ¸Ń â ĐžŃониŃŃ ĐżĐžĐşĐ°ĐˇĐ°ŃоНи каŃĐľŃŃва МиСни, ŃвŃСаннОгО ŃĐž СдОŃОвŃоП (health-related quality-of-life, HRQOL), пО даннŃĐź иŃŃĐťĐľĐ´ĐžĐ˛Đ°Đ˝Đ¸Ń CLEAR.ĐĐ°ŃĐľŃĐ¸Đ°ĐťŃ Đ¸ ПоŃОдŃ. ĐŃĐşŃŃŃОо ŃандОПиСиŃОваннОо кНиниŃĐľŃкОо иŃŃНодОванио III ŃĐ°ĐˇŃ ĐąŃНО ĐżŃОводонО на йаСо 200 НоŃойнŃŃ
ŃŃŃоМдониК и ОнкОНОгиŃĐľŃкиŃ
ŃонŃŃОв в 20 ŃŃŃанаŃ
ПиŃĐ°. ĐŃиŃĐľŃии вкНŃŃĐľĐ˝Đ¸Ń ĐżĐ°ŃионŃОв: вОСŃĐ°ŃŃ ŃŃĐ°ŃŃĐľ 18 НоŃ, ŃĐ°ŃĐżŃĐžŃŃŃаноннŃĐš ŃвоŃНОкНоŃĐžŃĐ˝ŃĐš пОŃĐľŃнО-кНоŃĐžŃĐ˝ŃĐš ŃĐ°Đş, ОйŃĐľŃОПаŃиŃĐľŃкиК ŃŃĐ°ŃŃŃ ĐżĐž ŃкаНо ĐĐ°ŃнОвŃкОгО 70 % иНи вŃŃĐľ. ĐĐ°ŃионŃОв, кОŃĐžŃŃĐź Ńаноо ĐżŃОвОдиНаŃŃ ĐżŃĐžŃивООпŃŃ
ĐžĐťĐľĐ˛Đ°Ń ĐťĐľĐşĐ°ŃŃŃĐ˛ĐľĐ˝Đ˝Đ°Ń ŃĐľŃĐ°ĐżĐ¸Ń ĐżĐžŃĐľŃнО-кНоŃĐžŃнОгО Ńака, но вкНŃŃаНи в иŃŃНодОванио. ĐŃĐľ паŃионŃŃ ĐąŃНи ŃандОПиСиŃĐžĐ˛Đ°Đ˝Ń (1:1:1) на 3 ĐłŃŃппŃ: кОПйинаŃĐ¸Ń ĐťĐľĐ˝Đ˛Đ°Ńинийа (20 Пг/ŃŃŃ, внŃŃŃŃ) Ń ĐżĐľĐźĐąŃОНиСŃПайОП (200 Пг, внŃŃŃивоннО, каМдŃĐš 21 донŃ), кОПйинаŃĐ¸Ń ĐťĐľĐ˝Đ˛Đ°Ńинийа (18 Пг/ŃŃŃ, внŃŃŃŃ) Ń ŃвоŃОНиПŃŃОП (5 Пг/ŃŃŃ, внŃŃŃŃ) 21-дновнŃĐš ŃикН и ПОнОŃĐľŃĐ°ĐżĐ¸Ń ŃŃниŃинийОП (50 Пг/ŃŃŃ, внŃŃŃŃ, ŃоМиП 4/2: 28 дноК НоŃĐľĐ˝Đ¸Ń Ń ĐżĐžŃНодŃŃŃиП поŃĐľŃŃвОП 14 дноК, 42-дновнŃĐš ŃикН НоŃониŃ). ĐĐ°ŃионŃŃ ĐąŃНи ŃĐ°ŃĐżŃĐľĐ´ĐľĐťĐľĐ˝Ń Đ˝Đ° ĐłŃŃĐżĐżŃ ĐťĐľŃĐľĐ˝Đ¸Ń Ń ĐżĐžĐźĐžŃŃŃ ĐşĐžĐźĐżŃŃŃĐľŃнОК ŃŃ
ĐľĐźŃ ŃандОПиСаŃии и ŃŃŃĐ°ŃиŃиŃиŃĐžĐ˛Đ°Đ˝Ń ĐżĐž гоОгŃĐ°ŃиŃĐľŃкиП ŃогиОнаП и ĐżŃОгнОŃŃиŃĐľŃкиП ĐłŃŃппаП Memorial Sloan Kettering Cancer Center. ĐĐľŃвиŃнОК кОноŃнОК ŃĐžŃкОК иŃŃĐťĐľĐ´ĐžĐ˛Đ°Đ˝Đ¸Ń ĐąŃНа вŃМиваоПОŃŃŃ ĐąĐľĐˇ ĐżŃОгŃĐľŃŃиŃОваниŃ, вŃĐžŃиŃнОК кОноŃнОК ŃĐžŃкОК â ĐžŃонка HRQOL. ĐŃĐľĐ˝ĐşŃ HRQOL ĐżŃОвОдиНи Ń ĐżĐ°ŃионŃОв, ĐżŃĐžŃодŃиŃ
ŃандОПиСаŃиŃ, кОŃĐžŃŃĐľ пОНŃŃиНи пО ĐşŃаКноК ПоŃĐľ 1 Đ´ĐžĐˇŃ Đ¸ŃŃНодŃоПОгО ĐżŃопаŃĐ°ŃĐ° и СапОНниНи даннŃĐľ Đž HRQOL. ĐнаНиС пОкаСаŃоНоК СавоŃŃĐľĐ˝Đ¸Ń Đ¸ ŃОйНŃĐ´ĐľĐ˝Đ¸Ń ŃŃойОваниК (ŃООŃвоŃŃŃвиŃ) вŃпОНнŃНи ĐżŃи пОНнОП найОŃĐľ инŃŃŃŃПонŃОв иŃŃНодОваниŃ. ĐнкоŃиŃОванио Ń Đ¸ŃпОНŃСОваниоП ОпŃĐžŃника ŃŃнкŃиОнаНŃнОК ĐžŃонки индокŃĐ° ŃиПпŃОПОв ŃĐľŃапии Ńака пОŃки и ŃиПпŃОПОв, ŃвŃСаннŃŃ
Ń ĐˇĐ°ĐąĐžĐťĐľĐ˛Đ°Đ˝Đ¸ĐľĐź (Functional Assessment of Cancer Therapy Kidney Symptom Index-Disease-Related Symptoms, FKSI-DRS), ОпŃĐžŃника каŃĐľŃŃва МиСни ĐвŃОпоКŃкОК ĐžŃганиСаŃии пО иŃŃĐťĐľĐ´ĐžĐ˛Đ°Đ˝Đ¸Ń Đ¸ НоŃĐľĐ˝Đ¸Ń Ńака (EORTC QLQ-C30) и ОпŃĐžŃника ĐвŃОпоКŃкОгО ŃОнда иŃŃĐťĐľĐ´ĐžĐ˛Đ°Đ˝Đ¸Ń ĐşĐ°ŃĐľŃŃва МиСни (EQ-5D-3L) ĐżŃОвОдиНи на иŃŃ
ОднОП ŃŃОвно и на 1-Đš Đ´ĐľĐ˝Ń ĐşĐ°ĐśĐ´ĐžĐłĐž пОŃНодŃŃŃогО 21-дновнОгО ŃикНа НоŃониŃ. ĐĐ°ŃŃĐžŃŃоо иŃŃНодОванио СаŃогиŃŃŃиŃОванО на ClinicalTrials.gov, NCT02811861 и в наŃŃĐžŃŃоо вŃĐľĐźŃ ĐˇĐ°ĐşŃŃŃĐž Đ´ĐťŃ Đ˝Đ°ĐąĐžŃĐ° нОвŃŃ
ŃŃĐ°ŃŃникОв.РоСŃĐťŃŃĐ°ŃŃ. РпоŃиОд Ń 13 ОкŃŃĐąŃŃ 2016 Đł. пО 24 иŃĐťŃ 2019 Đł. 355 паŃионŃОв ĐąŃНи ŃандОПиСиŃĐžĐ˛Đ°Đ˝Ń Đ˛ ĐłŃŃĐżĐżŃ ĐťĐľŃĐľĐ˝Đ¸Ń ĐşĐžĐźĐąĐ¸Đ˝Đ°ŃиоК НонваŃинийа и поПйŃОНиСŃПайа, 357 паŃионŃОв â в ĐłŃŃĐżĐżŃ ĐşĐžĐźĐąĐ¸Đ˝Đ°Ńии НонваŃинийа и ŃвоŃОНиПŃŃĐ° и 357 паŃионŃОв â в ĐłŃŃĐżĐżŃ ĐźĐžĐ˝ĐžŃĐľŃапии ŃŃниŃинийОП. Đодиана вŃоПони найНŃĐ´ĐľĐ˝Đ¸Ń Đ´ĐťŃ Đ°Đ˝Đ°ĐťĐ¸ĐˇĐ° ĐžŃонки HRQOL ŃĐžŃŃавиНа 12,9 ĐźĐľŃ (ПоМкваŃŃиНŃĐ˝ŃĐš диапаСОн 5,6â22,3 ПоŃ). ĐС-Са дОкаСаннОК вŃŃОкОК ŃŃŃокŃивнОŃŃи и ĐżŃĐžŃĐ¸ĐťŃ ĐąĐľĐˇĐžĐżĐ°ŃнОŃŃи кОПйинаŃии НонваŃинийа и поПйŃОНиСŃПайа в 1-Đš Нинии ĐżŃĐžŃивООпŃŃ
ОНовОгО НоŃĐľĐ˝Đ¸Ń ŃĐ°ŃĐżŃĐžŃŃŃаноннОгО пОŃĐľŃнО-кНоŃĐžŃнОгО Ńака ĐžŃĐ˝ĐžĐ˛Đ˝Đ°Ń ŃĐ°ŃŃŃ Đ˝Đ°ŃŃĐžŃŃогО анаНиСа ĐžŃонки HRQOL пОŃвŃŃона ŃŃавниŃоНŃĐ˝ĐžĐźŃ Đ¸ĐˇŃŃĐľĐ˝Đ¸Ń ŃŃОК кОПйинаŃии и ПОнОŃĐľŃапии ŃŃниŃинийОП. ĐĄŃодноо иСПононио ĐžŃ Đ¸ŃŃ
ОднОгО ŃŃĐžĐ˛Đ˝Ń HRQOL в ĐłŃŃппо кОПйинаŃии НонваŃинийа и поПйŃОНиСŃПайа пО ŃŃĐ°Đ˛Đ˝ĐľĐ˝Đ¸Ń Ń ĐłŃŃппОК ПОнОŃĐľŃапии ŃŃниŃинийОП ŃĐžŃŃавиНО â1,75 (ŃŃандаŃŃĐ˝Đ°Ń ĐžŃийка (ĐĄĐ) 0,59) ĐżŃĐžŃив â2,19 (ĐĄĐ 0,66) пО ОпŃĐžŃĐ˝Đ¸ĐşŃ FKSI-DRS, â5,93 (ĐĄĐ 0,86) ĐżŃĐžŃив â6,73 (ĐĄĐ 0,94) пО ОпŃĐžŃĐ˝Đ¸ĐşŃ EORTC QLQ-C30 GHS/QOL (ŃкаНа ОйŃогО ŃŃĐ°ŃŃŃĐ° СдОŃОвŃŃ/каŃĐľŃŃва МиСни) и â4,96 (ĐĄĐ 0,85) ĐżŃĐžŃив â6,64 (ĐĄĐ 0,94) пО виСŃĐ°ĐťŃнОК анаНОгОвОК ŃкаНо EQ-5D-3L. Đодиана вŃоПони Đ´Đž поŃвОгО ŃŃ
ŃĐ´ŃĐľĐ˝Đ¸Ń HRQOL в ĐłŃŃппо кОПйинаŃии НонваŃинийа и поПйŃОНиСŃПайа пО ŃŃĐ°Đ˛Đ˝ĐľĐ˝Đ¸Ń Ń ĐłŃŃппОК ПОнОŃĐľŃапии ŃŃниŃинийОП ŃĐžŃŃавиНа 9,14 нод (95 % дОвоŃиŃоНŃĐ˝ŃĐš инŃĐľŃваН (ĐĐ) 6,43â12,14) ĐżŃĐžŃив 12,14 нод (95 % ĐĐ 9,14â15,29; ĐžŃнОŃонио ŃиŃкОв (ĐĐ ) 1,13 (95 % ĐĐ 0,94â1,35); log-rank p = 0,20) пО ОпŃĐžŃĐ˝Đ¸ĐşŃ FKSI-DRS, 12,00 нод (95 % ĐĐ 7,29â15,14 ) ĐżŃĐžŃив 9,14 нод (95 % ĐĐ 6,29â12,14; ĐĐ 0,88 (95 % ĐĐ 0,74â1,05); log-rank p = 0,17) пО ОпŃĐžŃĐ˝Đ¸ĐşŃ EORTC QLQ-C30 GHS/QOL и 9,43 нод (95 % ĐĐ 6,43â12,29) ĐżŃĐžŃив 9,14 нод (95 % ĐĐ 6,29â12,00; ĐĐ 0,83 (95 % ĐĐ 0,70â0,99); log-rank p = 0,041) пО виСŃĐ°ĐťŃнОК анаНОгОвОК ŃкаНо EQ-5D-3L. Đодиана вŃоПони Đ´Đž ОкОнŃĐ°ŃоНŃнОгО ŃŃ
ŃĐ´ŃĐľĐ˝Đ¸Ń HRQOL в ĐłŃŃппо кОПйинаŃии НонваŃинийа и поПйŃОНиСŃПайа пО ŃŃĐ°Đ˛Đ˝ĐľĐ˝Đ¸Ń Ń ĐłŃŃппОК ПОнОŃĐľŃапии ŃŃниŃинийОП ŃĐžŃŃавиНа 134,14 нод (95 % ĐĐ 120,00âно Đ´ĐžŃŃигнŃŃĐ°) ĐżŃĐžŃив 117,43 нод (95 % ĐĐ 90,14â131,29; ĐĐ 0,70 (95 % ĐĐ 0,53â0,92); log-rank p = 0,0081) пО ОпŃĐžŃĐ˝Đ¸ĐşŃ FKSI-DRS, 114,29 нод (95 % ĐĐ 102,14â153,29) ĐżŃĐžŃив 75,14 нод (95 % ĐĐ 57,29â105,14; ĐĐ 0,60 (95 % ĐĐ 0,47â0,77); log-rank p <0,0001) пО ОпŃĐžŃĐ˝Đ¸ĐşŃ EORTC QLQ-C30 GHS/QOL и 124,86 нод (95 % ĐĐ 94,71â134,57) ĐżŃĐžŃив 74,86 нод (95 % ĐĐ 54,14â96,00; ĐĐ 0,67 (95 % ĐĐ 0,53â0,85); log-rank p = 0,0012) пО виСŃĐ°ĐťŃнОК анаНОгОвОК ŃкаНо EQ-5D-3L. Đи Один иС инŃŃŃŃПонŃОв ĐžŃонки HRQOL но пОкаСаН СнаŃиŃоНŃнОгО ĐżŃоиПŃŃĐľŃŃва в пОНŃĐˇŃ ŃŃниŃинийа поŃод кОПйинаŃиоК НонваŃинийа и поПйŃОНиСŃПайа. ĐŃи ĐžŃонко HRQOL Đ´ĐťŃ ĐşĐžĐźĐąĐ¸Đ˝Đ°Ńии НонваŃинийа и ŃвоŃОНиПŃŃĐ° пО ŃŃĐ°Đ˛Đ˝ĐľĐ˝Đ¸Ń Ń ĐźĐžĐ˝ĐžŃĐľŃапиоК ŃŃниŃинийОП в йОНŃŃинŃŃво ŃĐťŃŃаов пОкаСаŃоНи ĐąŃНи ŃŃ
ОМиПи иНи ĐżŃодпОŃŃиŃоНŃĐ˝ŃПи в пОНŃĐˇŃ ŃŃниŃинийа.ĐакНŃŃонио. РоСŃĐťŃŃĐ°ŃŃ Đ°Đ˝Đ°ĐťĐ¸ĐˇĐ° ĐžŃонки HRQOL пОкаСаНи, ŃŃĐž паŃионŃŃ, пОНŃŃĐ°ŃŃио НоŃонио кОПйинаŃиоК НонваŃинийа Ń ĐżĐľĐźĐąŃОНиСŃПайОП, иПоŃŃ Đ°Đ˝Đ°ĐťĐžĐłĐ¸ŃĐ˝ŃĐľ иНи йОНоо йНагОпŃиŃŃĐ˝ŃĐľ пОкаСаŃоНи каŃĐľŃŃва МиСни, ŃвŃСаннОгО ŃĐž СдОŃОвŃоП, пО ŃŃĐ°Đ˛Đ˝ĐľĐ˝Đ¸Ń Ń ĐżĐ°ŃионŃаПи, пОНŃŃĐ°ŃŃиПи ПОнОŃĐľŃĐ°ĐżĐ¸Ń ŃŃниŃинийОП, ĐžŃОйоннО в ĐžŃнОŃонии вŃоПони Đ´Đž ОкОнŃĐ°ŃоНŃнОгО ŃŃ
ŃĐ´ŃониŃ. РоСŃĐťŃŃĐ°ŃŃ Đ´Đ°Đ˝Đ˝ĐžĐłĐž иŃŃĐťĐľĐ´ĐžĐ˛Đ°Đ˝Đ¸Ń ĐżĐžĐ´ŃвоŃМдаŃŃ ŃŃŃокŃивнОŃŃŃ Đ¸ йоСОпаŃнОŃŃŃ ĐżŃĐ¸ĐźĐľĐ˝ĐľĐ˝Đ¸Ń ĐşĐžĐźĐąĐ¸Đ˝Đ°Ńии НонваŃинийа и поПйŃОНиСŃПайа в каŃĐľŃŃво 1-Đš Нинии ĐżŃĐžŃивООпŃŃ
ОНовОК ŃĐľŃапии Ń ĐżĐ°ŃионŃОв Ń ŃĐ°ŃĐżŃĐžŃŃŃаноннŃĐź пОŃĐľŃнО-кНоŃĐžŃĐ˝ŃĐź ŃакОП
Recommended from our members
A Search for Dark Higgs Bosons
Recent astrophysical and terrestrial experiments have motivated the proposal
of a dark sector with GeV-scale gauge boson force carriers and new Higgs
bosons. We present a search for a dark Higgs boson using 516 fb-1 of data
collected with the BABAR detector. We do not observe a significant signal and
we set 90% confidence level upper limits on the product of the Standard
Model-dark sector mixing angle and the dark sector coupling constant.Comment: 7 pages, 5 postscript figures, published version with improved plots
for b/w printin
Search for the standard model Higgs boson in the H to ZZ to 2l 2nu channel in pp collisions at sqrt(s) = 7 TeV
A search for the standard model Higgs boson in the H to ZZ to 2l 2nu decay
channel, where l = e or mu, in pp collisions at a center-of-mass energy of 7
TeV is presented. The data were collected at the LHC, with the CMS detector,
and correspond to an integrated luminosity of 4.6 inverse femtobarns. No
significant excess is observed above the background expectation, and upper
limits are set on the Higgs boson production cross section. The presence of the
standard model Higgs boson with a mass in the 270-440 GeV range is excluded at
95% confidence level.Comment: Submitted to JHE
- âŚ